(Q37703901)

22 August 2017

1 reference

title

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment (English)

1 reference

22 August 2017

1 reference

2

D Lambrechts

1 reference

22 August 2017

6

I Vergote

1 reference

22 August 2017

E Despierre

1

1 reference

22 August 2017

P Neven

series ordinal

3

1 reference

22 August 2017

F Amant

series ordinal

4

1 reference

22 August 2017

S Lambrechts

series ordinal

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

7 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

117

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

358-365

1 reference

22 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Chromosomal abnormalities in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

High-throughput oncogene mutation profiling in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

The biology of ovarian cancer: new opportunities for translation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

When mutants gain new powers: news from the mutant p53 field.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

The p53 tumor suppressor gene frequently is altered in gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Critical evaluation of p53 as a prognostic marker in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Characterizing the cancer genome in lung adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Mutation of the PIK3CA gene in ovarian and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

PTEN and the PI3-kinase pathway in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Hereditary ovarian cancer--assessing risk and prevention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

The potential of PARP inhibitors in genetic breast and ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

PIK3CA is implicated as an oncogene in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Promoter hypermethylation profile of ovarian epithelial neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

DNA hypomethylation and ovarian cancer biology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene-expression signatures in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Molecular profiling of platinum resistant ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Linking oncogenic pathways with therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNAs make big impression in disease after disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA expression in cytogenetically normal acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Endogenous human microRNAs that suppress breast cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

microRNAs exhibit high frequency genomic alterations in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA signatures in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA expression and identification of putative miRNA targets in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

MicroRNA expression profiles in serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.02.012

10.1016/J.YGYNO.2010.02.012

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference